CA125 蛋白, Human (HEK293, His)

CA125 is a giant mucin-like glycoprotein expressed by epithelial ovarian neoplasms and cells, which is an antigenic tumor marker. CA125 provides a protective, lubricating barrier against particles and infectious agents at mucosal surfaces. CA125 binds to mesothelin (MSLN) mediates heterotypic cell adhesion, contributing to the metastasis of ovarian cancer to the peritoneum by initiating cell attachment to the mesothelial epithelium. CA125 is widely used for monitoring with ovarian epithelial cancer. CA125 Protein, Human (HEK293, His) is a recombinant human cancer antigen 125 (CA125) with a His label and is expressed in HEK293 cells^{[1][2][3][4][5][6][7]}.

CA125 蛋白 (Human) 是半乳糖凝集素-1 的对抗受体，因为从 HeLa 细胞裂解物中提取的 CA125 可溶性片段和膜相关片段都被证明能高效地特异性结合人半乳糖凝集素-1^[1]。
CA125 蛋白 (Human) 是一种粘蛋白家族的蛋白质，是多种肿瘤的血清肿瘤标志物，例如卵巢癌、子宫内膜癌、胰腺癌和膀胱癌^[2]。
CA125 蛋白 (Human) 与膈膜上的腹膜癌症及残余疾病 (RD) 相关：CA-125 (Human) 值超过 500 U/mL 时，膈膜癌症的风险增加3.5 倍，而任何大小的残余疾病的风险增加 2.4 倍^[3]。
CA125 蛋白 (Human) 是存在于粘蛋白 16 (MUC16) 上的一种抗原表位，是一种存在于细胞表面的糖蛋白抗原。目前，有三种抗体可以帮助识别 CA125 抗原：OC125 类抗体，M11 类抗体和 OV197 类抗体。绝经后女性的 CA125 蛋白 (Human) 水平超过 35 U/mL，就被认为有较高的恶性肿瘤风险^[4]。
CA125 蛋白 (Human) 影响癌细胞的细胞功能，包括抵御细胞毒性自然杀伤细胞的攻击，以及调节肿瘤微环境 (TM) 中癌细胞或非癌细胞的细胞内信号通路^[5]。

CA125 蛋白 (Human) 的 N- 和 O- 连接糖基团以及其蛋白质核心结构共同对凝集素的特异性招募起到重要作用。此外，CA125-C-TERM 与凝集素-1 的结合在很大程度上依赖于 O-连接的 β-半乳糖苷末端的寡聚糖链^[1]。
CA125 蛋白 (Human) 高表达组中 M2 巨噬细胞标志物 CD163 和调节性 T 细胞 (Treg) 标志物 FOXP3 的表达水平高于 CA125 蛋白 (Human) 低表达组，这表明 CA125 蛋白 (Human) 高表达的膀胱癌具有免疫抑制的肿瘤微环境 (iTM)^[5]。

在携带 OVA-5 异种移植的无毛鼠中， CA125 蛋白 (Human) 与单克隆抗体 196-14 的亲和力比与单克隆抗体 196-28 的亲和力更高^[7]。

1. Immobilized Human Mesothelin at 10 μg/mL (100 μl/well) can bind recombinant Human CA125, His (HEK293-expressed) (rHuCA125, His).The ED₅₀ of recombinant Human CA125, His (HEK293-expressed) (rHuCA125, His) is ≤2 μg/mL.
2. Immobilized Recombinant Human MSLN/Mesothelin Protein at 2 μg/mL (100 μl/well) can bind Biotinylated Recombinant Human CA125 Protein. The ED₅₀ for this effect is 5.731 ng/mL, corresponding to a specific activity is 1.74×10⁵ Unit/mg.

• 
  Immobilized Recombinant Human MSLN/Mesothelin Protein at 2 μg/mL (100 μl/well) can bind Biotinylated Recombinant Human CA125 Protein. The ED₅₀ for this effect is 5.731 ng/mL, corresponding to a specific activity is 1.74×10⁵ Unit/mg.

Human

HEK293

C-6*His

Q8WXI7 (G12660-M12923)

94025  [NCBI]

GFTHWIPVPTSSTPGTSTVDLGSGTPSSLPSPTTAGPLLVPFTLNFTITNLKYEEDMHCPGSRKFNTTERVLQSLLGPMFKNTSVGPLYSGCRLTLLRSEKDGAATGVDAICTHRLDPKSPGVDREQLYWELSQLTNGIKELGPYTLDRNSLYVNGFTHQTSAPNTSTPGTSTVDLGTSGTPSSLPSPTSAGPLLVPFTLNFTITNLQYEEDMHHPGSRKFNTTERVLQGLLGPMFKNTSVGLLYSGCRLTLLRPEKNGAATGMHHHHHH

40-80 kDa

• 
  Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末.

Lyophilized after extensive dialysis against 50 mM Tris, 100 mM Glycine, pH 7.5 or 50 mM Tris-HCL, 300 mM NaCl, 100 mM Glycine, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Claudia Seelenmeyer, et al. The cancer antigen CA125 represents a novel counter receptor for galectin-1. J Cell Sci. 2003 Apr 1;116(Pt 7):1305-18.  [Content Brief]

  [2]. Jacobs I,et al. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989 Jan;4(1):1-12.  [Content Brief]

  [3]. Plana A, et al. Radiologically enlarged cardiophrenic lymph nodes and CA-125 in relation to diaphragmatic carcinomatosis, surgical outcome, and overall survival in advanced ovarian cancer. Acta Oncol. 2023 May;62(5):451-457.  [Content Brief]

  [4]. Zhang R, et al. Molecular Biomarkers for the Early Detection of Ovarian Cancer. Int J Mol Sci. 2022 Oct 10;23(19):12041.  [Content Brief]

  [5]. Yamashita T, et al. Cancer Antigen 125 Expression Enhances the Gemcitabine/Cisplatin-Resistant Tumor Microenvironment in Bladder Cancer. Am J Pathol. 2023 Mar;193(3):350-361.  [Content Brief]

  [6]. Kobayashi H, et al. A human/mouse chimeric monoclonal antibody against CA125 for radioimmunoimaging of ovarian cancer. Cancer Immunol Immunother. 1993 Aug;37(3):143-9.  [Content Brief]

  [7]. Saga T, et al. An antibody-tumor model for the targeting of CA125-producing gynecologic malignancies[J]. Japanese journal of cancer research, 1990, 81(11): 1141-1148.  [Content Brief]